Intuniv XR Coverage by Ontario Public Drug Program (OPDP)

CADDAC was just notified of the recommendation by the Committee to Evaluate Drugs or CED (part of OPDP) as a follow-up on our advocacy efforts to have Intuniv XR covered under the Ontario Public Drug Plan. The CED has recommended that Intuniv XR be reimbursed under the Exceptional Access Program (EAP) for children with ADHD…

Important follow-up on “Prescribing of ADHD stimulants has soared in B.C., agency warns”

This past weekend an important opinion piece, written by several prominent BC ADHD experts was published in “The Province”, a daily newspaper published in BC. The piece entitled, “Opinion: ADHD is a real brain disorder requiring treatment, despite what some say” opens with a request that BC medical colleagues demand that the Therapeutics Initiative, which…

Comment on Vancouver Sun article – Prescribing of ADHD stimulants has soared in B.C., agency warns

After receiving numerous e-mails from people unset about this article asking CADDAC to respond, CADDAC submitted this letter to the editor of the Vancouver Sun. Unfortunately the restricted number of words did not allow me to cover all the issues I had with this article, but the hope is that others will also contact the…

ADHD Gene Testing

Provided to CADDAC by Gina Pera author and educator In recent years, biomedical research has identified many “drug-response genes.”  These are genes that wield a substantial impact on how people react to medications. Several companies are making consumer-level tests available, with ADHD medications as well as with medications for depression and more. These purport to identify the kind…